Login to Your Account


Aslan's gastric cancer candidate enters the clinic in Taiwan

By Dave Silver
Staff Writer

Wednesday, September 10, 2014
TAIPEI, Taiwan – Oncology-focused Aslan Pharmaceuticals Pte. Ltd. has started dosing the first patients in a safety study of its lead compound ASLAN001, a small-molecule, oral pan-HER inhibitor for the treatment of solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription